RB 90740

04/01/1995 - "Despite these properties demonstrated in vitro, RB 90740 was shown not to be cytotoxic to hypoxic cells in experimental murine tumors in vivo. "
01/01/1996 - "This new series of bioreductive compounds may be effective in cancer therapy, particularly the lead compound RB 90740. "
05/15/1994 - "To study the reduction of RB90740 (1), a fused pyrazine mono-N-oxide that has an oxic:hypoxic cytotoxicity ratio of > 10 in a range of murine and human tumor cells in vitro. "
01/01/1994 - "These compounds had differential cytotoxicities in vitro of up to 20 for 8-amino derivatives such as RB90740 and 65 for 8-aminoalkoxy derivatives such as 1,2-dihydro-8-(1-(demethylamino)ethoxy)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide, but were disappointing in vivo with a maximum growth delay of 10 days compared with 30 days for SR4233 in the RIF-1 tumor model. "
05/15/1994 - "RIF-1 tumors implanted intradermally in C3H mice were treated with either 50J photodynamic therapy or with 120 min clamping in combination with either misonidazole, pimonidazole, metronidazole, nimorazole, RB6145, RSU1069, SR4233, mitomycin-C, or RB90740. "

07/01/1996 - "In hypoxia, the bioreductive metabolites of RB 90740 were substantially more cytotoxic and induced a higher oncogenic transformation yield than the drug in air. "
05/15/1994 - "Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity."
02/15/2009 - "Its hypoxic cytotoxicity relationship value, HCR, was of the same order than those of other hypoxia selective cytotoxins (i.e., Mitomycine C, Misonidazole and the N-oxide RB90740). "